Trial Profile
Impact of rivaroxaban versus heparin bridging to warfarin on length of hopital stay and treatment costs for patients with low risk of pulmonary embolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Heparin; Warfarin
- Indications Pulmonary embolism
- Focus Therapeutic Use
- 20 Oct 2016 New trial record
- 22 Aug 2016 Primary endpoint (Total treatment costs) has been met, according to the article published in the Pharmacotherapy.
- 22 Aug 2016 Primary endpoint (Length of hospital stay) has been met, according to the article published in the Pharmacotherapy.